ValiRx signs agreement with Dundee University
ValiRx plc, the Nuneaton-based life sciences company focusing on early-stage cancer therapeutics and women's health, has signed an agreement with University of Dundee and its Drug Discovery Unit (DDU) to access research relating to novel therapeutic candidates. The first evaluation agreement under this agreement has also been signed.
The over-arching agreement is scheduled to be active for five years, during which time, the company will have the opportunity to review research projects from the DDU in areas aligned with the strategy of ValiRx with a view to initiating additional evaluation projects on pre-defined terms.
The first Evaluation Agreement under the framework focuses on investigating a lead series of therapeutic candidates in the increasingly important research area of pro-senescence (selectively promoting ageing of cancer cells to cease growth in tumours). This exciting area of research has potential to be effective in treating of multiple cancer types, and also many other disease areas, including those associated with healthy aging. This work builds upon previous ground-breaking research by Dundee and Barts Charity funded research by Prof Cleo Bishop, Professor of Senescence and Director of the Queen Mary University London Phenotypic Screening Facility.
Dr Suzy Dilly, CEO of ValiRx, said: "We are delighted to be able to streamline the process of reviewing and accessing the excellent research from University of Dundee's DDU, which will help to bring on evaluation projects more quickly. The strength of the DDU and research facilities at Dundee are very impressive and, having reviewed multiple projects from teams there over the past year, we believe that this evaluation agreement will be the first of a series of new projects that can be brought into our pipeline."
Dr Cathy Tralau-Stewart, CSO of ValiRx, said: "The Drug Discovery Unit (DDU) is housed within the School of Life Sciences at the University of Dundee and is a fully integrated drug discovery centre which utilises extensive, highly-respected industry expertise to support the development of therapeutics originating from academic research. This multi-disciplinary expertise is required for successful drug discovery and we look forward to working with the DDU to progress this exciting project and other innovative approaches. This evaluation agreement is an important step-forward in developing ValiRx's drug discovery pipeline."
Professor David Gray, Head of Biology and innovative targets portfolio lead at the DDU added:"We are delighted that our UKRI Impact Accelerator Award has enabled us to translate the groundbreaking work of our collaborator Cleo Bishop at Queen Mary University London, to the point where ValiRx see the potential for treating patients."
